Compare Cytokinetics Inc (CYTK) vs Fubotv Inc (FUBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Fubotv Inc — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while Fubotv Inc trades at $8.92 (market cap $1.02B). The key difference: Cytokinetics Inc is far larger — about 8.5× Fubotv Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Fubotv Inc for 35 Days on average.
| CYTK | FUBO | |
|---|---|---|
Market Cap | $8.62B | $1.02B |
Volume | 2,594,626 | 978,631 |
Sector | Health | Media |
52-Week High | $87.26 | $48.96 |
52-Week Low | $54.76 | $8.09 |
Typical Hold Time | 19 Days | 35 Days |
Enterprise Value | $8.72B | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.91, up 2.93% with bearish technical signals despite strong analyst support. The company shows promising drug development with positive Phase 3 results for aficamten in HCM treatment, though fundamentals remain challenged with a P/S ratio of 114 and negative profit margins. Recent executive stock sales and high cash burn from operations highlight ongoing financial pressures despite growing revenue potential from new drug launches.
The outlook balances significant upside potential from analyst price targets averaging $112.60 against substantial execution risks. While clinical successes position CYTK for growth in cardiovascular treatments, persistent losses and high valuation metrics require careful risk assessment. The stock offers speculative growth opportunity but demands close monitoring of commercialization progress and path to profitability.
FUBO trades at $8.84, down 4.43% today, with bearish technical signals from moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and a projected net profit of $123M in 2025. Recent developments include new sports streaming agreements with NHL and TBL Team Boxing League, while analyst consensus remains mixed with 47% buy ratings and a $63.38 price target.
FUBO presents a turnaround story with improving profitability metrics and strategic content partnerships driving growth potential. However, risks include persistent negative cash flow, high debt levels, and intense streaming competition. The stock's current valuation appears attractive with P/E of 2.43 and P/S of 0.19, but execution risks remain significant for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
